Cambridge Investment Research Advisors, Inc. Sellas Life Sciences Group, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $36.4 Billion
- Q3 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 20,000 shares of SLS stock, worth $28,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,000Holding current value
$28,600% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SLS
# of Institutions
101Shares Held
27.8MCall Options Held
3.85MPut Options Held
126K-
Vanguard Group Inc Valley Forge, PA6.84MShares$9.78 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX6.03MShares$8.63 Million1.59% of portfolio
-
Marshall Wace, LLP London, X02.36MShares$3.37 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.26MShares$3.24 Million0.0% of portfolio
-
State Street Corp Boston, MA1.36MShares$1.95 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $29.4M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...